# OnCo record relatlimab-nivolumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/relatlimab-nivolumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "relatlimab-nivolumab" ;
  schema:name "Relatlimab + nivolumab"@en ;
  schema:description "Opdualag combines relatlimab, the first drug targeting the LAG-3 immune brake, with nivolumab for melanoma."@en ;
  schema:url <https://onco.cc/drugs/relatlimab-nivolumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nivolumab/relatlimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q111370719> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relatlimab> ;
  onco:status "approved" ;
  onco:modality "Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)" ;
  schema:alternateName "Opdualag" ;
  onco:approval "US 2022: Unresectable or metastatic melanoma, age ≥12", "EU 2022: Melanoma, PD-L1 <1% restriction" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct06246916/>, <https://onco.cc/trials/nct05625399/>, <https://onco.cc/trials/nct06101134/>, <https://onco.cc/trials/nct05970497/> .